1. Home
  2. BGLC vs IDAI Comparison

BGLC vs IDAI Comparison

Compare BGLC & IDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BGLC
  • IDAI
  • Stock Information
  • Founded
  • BGLC 2017
  • IDAI 2016
  • Country
  • BGLC Malaysia
  • IDAI United States
  • Employees
  • BGLC N/A
  • IDAI N/A
  • Industry
  • BGLC Medical Specialities
  • IDAI Computer Software: Prepackaged Software
  • Sector
  • BGLC Health Care
  • IDAI Technology
  • Exchange
  • BGLC Nasdaq
  • IDAI Nasdaq
  • Market Cap
  • BGLC 10.4M
  • IDAI 7.7M
  • IPO Year
  • BGLC N/A
  • IDAI N/A
  • Fundamental
  • Price
  • BGLC $5.72
  • IDAI $2.86
  • Analyst Decision
  • BGLC
  • IDAI
  • Analyst Count
  • BGLC 0
  • IDAI 0
  • Target Price
  • BGLC N/A
  • IDAI N/A
  • AVG Volume (30 Days)
  • BGLC 64.8K
  • IDAI 25.9K
  • Earning Date
  • BGLC 08-18-2025
  • IDAI 08-14-2025
  • Dividend Yield
  • BGLC N/A
  • IDAI N/A
  • EPS Growth
  • BGLC N/A
  • IDAI N/A
  • EPS
  • BGLC N/A
  • IDAI N/A
  • Revenue
  • BGLC $9,551,559.00
  • IDAI $3,366,415.00
  • Revenue This Year
  • BGLC N/A
  • IDAI $25.13
  • Revenue Next Year
  • BGLC N/A
  • IDAI $48.09
  • P/E Ratio
  • BGLC N/A
  • IDAI N/A
  • Revenue Growth
  • BGLC 4.01
  • IDAI N/A
  • 52 Week Low
  • BGLC $2.01
  • IDAI $1.43
  • 52 Week High
  • BGLC $15.60
  • IDAI $18.75
  • Technical
  • Relative Strength Index (RSI)
  • BGLC 54.48
  • IDAI 50.28
  • Support Level
  • BGLC $5.45
  • IDAI $2.85
  • Resistance Level
  • BGLC $5.72
  • IDAI $3.06
  • Average True Range (ATR)
  • BGLC 0.24
  • IDAI 0.17
  • MACD
  • BGLC -0.01
  • IDAI 0.00
  • Stochastic Oscillator
  • BGLC 92.36
  • IDAI 50.63

About BGLC BioNexus Gene Lab Corp Common stock

BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.

About IDAI T Stamp Inc.

T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The artificial intelligence-powered solutions segment generates revenue principally from software licenses, professional services, and recurring Software-as-a-Service ("SaaS") revenue.

Share on Social Networks: